Everything you care about in one place
Follow feeds: blogs, news, RSS and more. An effortless way to read and digest content of your choice.
Get Feederpubmed.ncbi.nlm.nih.gov
Durva OR Treme OR Pembrolizumab OR nivolumab OR atezolizumab OR sasanlimab OR tarlatamab AND lung cancer AND 2025:2025[pdat] AND 2025:2025[pdat]
Get the latest updates from Durva OR Treme OR Pembrolizumab OR nivolumab OR atezolizumab OR sasanlimab OR tarlatamab AND lung cancer AND 2025:2025[pdat] AND 2025:2025[pdat] directly as they happen.
Follow now 166 followers
Latest posts
Last updated about 10 hours ago
Efficacy of continuing pembrolizumab after progression on first-line treatment in stage IV non-small cell lung cancer: a prospective real-world study
about 17 hours ago
Am J Cancer Res. 2025 Nov 25;15(11):4934-4944. doi: 10.62347/GFTO6440. eCollection 2025.ABSTRACTThis prospective...
Outcome of stage-eligible patients not receiving neoadjuvant chemo-immunotherapy for clinical or procedural reasons: a real practice analysis
1 day ago
Eur J Surg Oncol. 2025 Dec 11;52(2):111356. doi: 10.1016/j.ejso.2025.111356. Online ahead of...
Efficacy and Safety of Atezolizumab Plus Bevacizumab in Patients With Advanced NSCLC Who Received Pretreatment With EGFR-TKIs (ML41256): A Multicenter, Prospective, Single-Arm, Phase 2 Trial
3 days ago
Cancer Med. 2025 Dec;14(24):e71469. doi: 10.1002/cam4.71469.ABSTRACTBACKGROUND: Few treatment options are available for...
Frontline sigvotatug vedotin plus pembrolizumab vs pembrolizumab for non-small cell lung cancer with PD-L1 tumor proportion score 50%: phase III study design
3 days ago
Future Oncol. 2025 Dec 13:1-11. doi: 10.1080/14796694.2025.2596228. Online ahead of print.ABSTRACTIntegrin beta-6...
Efficacy and safety of immune checkpoint inhibitor rechallenge following immune-related adverse events: a review
3 days ago
Jpn J Clin Oncol. 2025 Dec 13:hyaf200. doi: 10.1093/jjco/hyaf200. Online ahead of...
Real-World Survival Outcomes of Atezolizumab and Bevacizumab in Unresectable Hepatocellular Carcinoma Patients With Hepatitis B Virus Infection: A Hospital-Based Cohort Study
3 days ago
Cancer Control. 2025 Jan-Dec;32:10732748251405547. doi: 10.1177/10732748251405547. Epub 2025 Dec 13.ABSTRACTBackgroundAtezolizumab-Bevacizumab is one...
Long-term outcomes of preoperative nivolumab with or without relatlimab in patients with resectable non-small-cell lung cancer (NEOpredict-Lung)
3 days ago
Eur J Cancer. 2025 Dec 5;233:116165. doi: 10.1016/j.ejca.2025.116165. Online ahead of print.ABSTRACTBACKGROUND...
Impact of pembrolizumab on health outcomes and productivity in earlier-stage cancers within the US Medicare population
3 days ago
J Med Econ. 2025 Dec;28(1):2186-2197. doi: 10.1080/13696998.2025.2599670. Epub 2025 Dec 13.ABSTRACTAIM: Pembrolizumab...
A phase III placebo-controlled study of eftilagimod alfa plus pembrolizumab and chemotherapy in metastatic non-small cell lung cancer
4 days ago
Future Oncol. 2025 Dec 12:1-6. doi: 10.1080/14796694.2025.2597404. Online ahead of print.ABSTRACTBACKGROUND: Although...
Extended Follow-Up Analysis of First-Line Atezolizumab in Extensive-Stage Small Cell Lung Cancer: A Real-World Multicenter Prospective Cohort Study
4 days ago
Thorac Cancer. 2025 Dec;16(23):e70201. doi: 10.1111/1759-7714.70201.ABSTRACTBACKGROUND: We previously reported the short-term real-world...
Beyond the Skin: A Rare Case of Primary Malignant Melanoma of the Lung
4 days ago
Cureus. 2025 Nov 10;17(11):e96502. doi: 10.7759/cureus.96502. eCollection 2025 Nov.ABSTRACTPrimary malignant melanoma of...
BI08 A prospective observational study exploring the incidence and impact of cutaneous toxicities in patients undergoing oncological treatment
4 days ago
Br J Dermatol. 2025 Jun 27;193(Supplement_1):ljaf085.417. doi: 10.1093/bjd/ljaf085.417.ABSTRACTPatients with cancer develop a...